Loading...
NPI 1023720778 · Jessup, PA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Unity Holding Groups LLC is a clinical medical laboratory provider located in Jessup, Pennsylvania. This profile covers 51 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Unity Holding Groups LLC |
| Address | 1 Alberigi Dr Ste 109 |
| City | Jessup |
| State | PA |
| ZIP | 18434 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 14, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $13M |
| Medicaid | $0 |
UNITY HOLDING GROUPS LLC operates as a clinical molecular laboratory with a clear emphasis on genetic sequencing and diagnostic testing. Its top billed codes are dominated by full-gene and targeted-sequence assays (examples include 81307, 81317, 81298, 81185, 81325 and tumor-associated assays such as 81191/81192), and claim counts in the top codes are typically in the 1.1K–1.7K range, indicating high-volume specimen processing rather than low-volume specialty procedural work.
Revenue is concentrated in a handful of high-value genetic tests: the three highest-revenue Medicare codes 81307 ($960K, 8.7% of Medicare revenue), 81317 ($953.4K, 8.6% of Medicare revenue), and 81298 ($922.7K, 8.3% of Medicare revenue) together account for 25.6% of this provider's total Medicare revenue. This concentration shows reliance on a small group of sequencing services for a large share of billings, highlighting those assays as key service lines for contracting or utilization review.
Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $13M while reported Medicaid revenue is $0, indicating the provider either does not participate in Medicaid or does not bill Medicaid in this data set. For payers and network planners, this means financial exposure and utilization patterns are driven almost entirely by Medicare policy and beneficiary referrals.
Competitive standing across national Medicare peers is mixed but notable for specific assays. UNITY ranks in the top decile nationally for several hereditary-sequencing codes (for example 81317 ranks #6 of 51 providers nationally at the 90th percentile and 81298 ranks #6 of 50 at the 90th percentile), while other frequently billed codes are described as "typical, unremarkable volume," reflecting a position as a significant niche player rather than a broad-market dominant laboratory.
There is at least one pronounced statistical outlier in the portfolio: 81364 (HBB full gene sequencing) is listed as $353K (3.2% of Medicare revenue) and ranks #1 of 11 providers nationally (100th percentile), described as an "extreme outlier, far above typical national volume for this code." That single-code dominance suggests a specialized capability or referral relationship for hemoglobinopathy testing that materially differentiates the provider from most peers.
Beyond the top three revenue drivers, the lab maintains a broad textbook portfolio of germline and targeted oncology tests with many codes showing large claim counts but "typical, unremarkable volume" relative to national peers (examples include 81185 $911.9K, 81325 $830.9K, 81249 $582.7K and 81309 $455.7K). This breadth implies the operation supports a wide range of genetic indications—hereditary disease panels, neuromuscular and repeat-expansion tests, and some tumor translocation assays—consistent with a full-service clinical molecular laboratory.
The provider’s NPI was enumerated on 2022-12-14 (~4 years ago), which is a relatively recent start date for an entity that already reports $13M in Medicare revenue. That combination of short tenure and rapid revenue accumulation may indicate fast scale-up through referral contracts, high-volume specimen sourcing, or centralized processing agreements rather than slow organic growth through local clinical volume.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
51 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 1,450 | $660 | $960K |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 1,440 | $660 | $953.4K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 1,470 | $630 | $922.7K |
| 81185 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the calcium voltage–gated channel subunit alpha1 A gene, also called CACNA1A. | 1,100 | $830 | $911.9K |
| 81325 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the peripheral myelin protein 22, or PMP22, gene. | 1,100 | $750 | $830.9K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 990 | $590 | $582.7K |
| 81302 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the methyl CpG binding protein 2, or MECP2 gene. | 1,110 | $520 | $572.3K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 940 | $590 | $555.1K |
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 290 | $1,790 | $514.9K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 990 | $490 | $482.2K |
Showing 1–10 of 51
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 51 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
51 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81307 | 2 | 10 | 1,600 | $660 | $1.1M |
| 81317 | 2 | 10 | 1,590 | $660 | $1.1M |
| 81298 | 2 | 10 | 1,610 | $630 | $1M |
| 81185 | 1 | 10 | 1,100 | $830 | $912.3K |
| 81325 | 1 | 10 | 1,100 | $750 | $831.1K |
| 81249 | 2 | 10 | 1,200 | $590 | $704.4K |
| 81238 | 2 | 10 | 1,160 | $590 | $679.1K |
| 81223 | 2 | 10 | 1,200 | $490 | $585.8K |
| 81302 | 1 | 10 | 1,110 | $520 | $572.7K |
| 81162 | 1 | 10 | 260 | $1,790 | $470.3K |
Showing 1–10 of 51
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 10 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 6 | 10 | 50 | $130 | $8K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.